Lupin Limited Debuts in Dow Jones Best-in-Class Indices 2026
Global pharmaceutical major Lupin Limited announced its inclusion in the Dow Jones Best-in-Class (DJBIC) Indices for 2026. The debut across both the DJBIC World Index and the DJBIC Emerging Markets Index highlights the company's strong commitment to sustainable, responsible, and ethical business practices.The inclusion in these prestigious indices recognizes companies that demonstrate exceptional performance across key Environmental, Social, and Governance (ESG) parameters, based on leading S&P Global CSA scores. The DJBIC World Index tracks top-performing companies globally, while the DJBIC Emerging Markets Index specifically highlights sustainability leaders across emerging economies.
Lupin previously demonstrated its commitment to sustainability when it was ranked among the top 1% globally in the S&P Global Corporate Sustainability Assessment (CSA) 2025, achieving an industry-leading score of 91/100.
Ramesh Swaminathan, Executive Director, Global CFO, Head of IT and API Plus SBU at Lupin, stated that the company's inclusion reflects the strength of its governance framework and financial discipline. He added that the recognition marks a meaningful advancement in the sustainability journey, reinforcing the long-term value creation agenda anchored in responsible growth and the continued commitment to delivering affordable, high-quality medicines worldwide.
Lupin remains dedicated to advancing its sustainability agenda through environmental stewardship, scientific basis targets, quality and safety standards, inclusive workplace practices, and responsible supply chain management, all aimed at creating long-term value for patients, communities, and stakeholders.
Understanding the Dow Jones Best-in-Class Indices
The Dow Jones Best-in-Class Indices (formerly DJSI) are float-adjusted market capitalization weighted indices. They measure the performance of selected companies that satisfy specific criteria based on the S&P Global CSA Scores using a best-in-class approach.The structure of the indices is defined as follows:
| Index Name | Tracking Focus | Selection Criteria |
|---|---|---|
| Dow Jones Best-in-Class World | Tracks the performance of top companies globally in terms of sustainability. | Top 10% of the 2,500 largest companies in the S&P Global Broad Market Index. |
| Dow Jones Best-in-Class Emerging Markets | Tracks the performance of sustainability leaders across emerging economies. | Top 10% of the 800 largest Emerging Markets companies in the S&P Global Broad Market Index. |
About Lupin Limited
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India. The company distributes products in over 100 markets and specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.The company has a strong presence in India and the U.S., covering multiple therapy areas such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin maintains 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by a dedicated workforce of over 24,000 professionals. Lupin also operates subsidiaries including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions, underlining its commitment to improving patient health outcomes.
LUPIN Stock Price Movement
Today, Lupin Limited shares edged higher to close at ₹2287.4, achieving a gain of 1.75% in post-market trading. The stock finished the day trading on a volume of 1.24 million shares, with the price range set between ₹2250.5 and ₹2294.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.